An interventional study of Experimental Tobacco Marketplace and Hypothetical Novel Nicotine Product Purchase Tasks in Alcohol Use, E-cigarette Use and Cigarette Use, sponsored by Mark J Rzeszutek, PhD. Completed at 1 site in United States. Open to participants aged 21 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-15.
Sponsored by Mark J Rzeszutek, PhD · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 288 studies in Vaping with a site in United States — 66 open to participants now, 74 under way, 1 of them phase 3. Vaping · United States.
Among the 288 studies in Vaping with a site in United States, this one is the 29th largest by enrollment of the 258 interventional ones that give a count, is one of 37 that started in 2025, is one of 206 with no phase, and was the 247th registered.
404 studies on the registry are indexed under Vaping; 97 are open to participants now.
Browse Vaping studies →66 of the 288 studies in Vaping with a site in United States are open now. Recruiting first, the newest first:
Medical University of South Carolina · Sites in United States
Ages 18+
University of Minnesota · Sites in United States
Ages 21+ · Healthy volunteers
Yale University · Sites in United States
Ages 21–44 · Healthy volunteers
Massachusetts General Hospital · Sites in United States
Ages 18–65
University of Nebraska · Sites in United States
Ages 15–18
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 65 Vaping studies recruiting now, 33 (51%) set no upper age limit and 31 (48%) stop at 75 or younger; 13 take children under 18; 40 take healthy volunteers.
This study: 21 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
288 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 18 · Phase 2 21 · Phase 3 4 · Phase 4 12
First in 2013; this study’s year is marked. 37 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 737 is above the median of 79 across 324 interventional studies indexed under Vaping.
Median enrollment 71 across the 258 interventional studies, 110 across the 30 observational. Of the 202 that completed or were terminated, 87 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
30 of 288 have an industry lead sponsor. The 10 most frequent:
Mark J Rzeszutek, PhD is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
Mark J Rzeszutek, PhD has 1 study filed under Vaping — fewer than ten, so there is no comparison to draw.
31 of the studies in Vaping with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07322432VapeAwayThe CONQUER Trial - Cessation Of Nicotine, QUitting With E-cigarette Reduction | 2026-12 |
| NCT06159608Anna Stanhewicz, PhDSex Differences in the Vascular Effects of E-cigarette Use | 2026-12 |
| NCT04661683University of California, Los AngelesSecondhand Effects of Hookah (i.e., Waterpipe) Smoke and Aerosol | 2026-12-15 |
| NCT07553585Yale UniversitySurvey to Test the Nicotine Concentration and Nicotine Flux Labels for E-cigarettes | 2026-12-15 |
| NCT04907136Florida International UniversityDeveloping and Testing Health Warning Labels on the ENDS Device | 2026-12-30 |
Add all 31 to your calendar (.ics) → With an account.
Among the 288 studies in Vaping with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A high priority research area for the Food and Drug Administration Center for Tobacco Products (FDA CTP) is determining who will start using tobacco products and who will stop using tobacco products. A population that has a disproportionately high amount of tobacco use are people living in rural areas. This indicates that some aspect of rurality is related to tobacco product susceptibility and decreased tobacco cessation rates. People in rural areas also typically have higher rates of alcohol use, which is also associated with higher tobacco use and decreased tobacco cessation rates. The purpose of this study is to (1) examine how rurality and alcohol use may affect susceptibility to existing and novel tobacco products and (2) examine how rurality and alcohol use may affect likelihood for tobacco users to substitute to tobacco cessation products. To accomplish this, the investigators will use behavioral economic measures to assess how people respond to novel tobacco products (high and low nicotine, flavored and unflavored), as well as use the experimental tobacco marketplace to determine how current users might switch to products associated with cessation. Because rurality is a spectrum, the investigators will be using an index of relative rurality (IRR) to better quantify how rurality and alcohol use affect these tobacco-related behaviors.
404 studies on the registry are indexed under Vaping; 97 are open to participants now.
This study's enrollment of 737 is above the median of 79 across 324 interventional studies indexed under Vaping.
Browse Vaping studies →Mark J Rzeszutek, PhD is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
Compared within Vaping, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Alcohol Drinking. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Cigarette/E-Cigarette Users
Inclusion Criteria:
Cigarette/E-Cigarette Non-Users
Inclusion Criteria:
Risky Alcohol Users
Inclusion Criteria:
Non-Risky Alcohol Users
Inclusion Criteria:
All groups
Inclusion Criteria:
Exclusion Critera:
Participants with low alcohol use and no cigarette or e-cigarette use will complete a Qualtrics survey consisting of various decision-making tasks, and novel hypothetical nicotine product demand tasks
Behavioral: Hypothetical Novel Nicotine Product Purchase Tasks
Participants with high alcohol use and no cigarette or e-cigarette use will complete a Qualtrics survey consisting of various decision-making tasks, and novel hypothetical nicotine product demand tasks.
Behavioral: Hypothetical Novel Nicotine Product Purchase Tasks
Participants with low alcohol use and cigarette or e-cigarette use will complete a Qualtrics survey consisting of various decision-making tasks, novel hypothetical nicotine product demand tasks, and Experimental Tobacco Marketplace scenarios (ETM). There will be three total ETM scenarios, cigarette adjusting price, e-cigarette adjusting price, and both e-cigarette and cigarette adjusting price.
Behavioral: Experimental Tobacco Marketplace · Behavioral: Hypothetical Novel Nicotine Product Purchase Tasks
Participants with high alcohol use and cigarette or e-cigarette usewill complete a Qualtrics survey consisting of various decision-making tasks, novel hypothetical nicotine product demand tasks, and Experimental Tobacco Marketplace scenarios (ETM). There will be three total ETM scenarios, cigarette adjusting price, e-cigarette adjusting price, and both e-cigarette and cigarette adjusting price.
Behavioral: Experimental Tobacco Marketplace · Behavioral: Hypothetical Novel Nicotine Product Purchase Tasks
This study will have three different scenarios in the Experimental Tobacco Marketplace (ETM) for participants who reported being cigarette and/or e-cigarette users. These will consist of hypothetical purchase scenarios where a variety of different tobacco products are available to purchase. The three ETM scenarios will be adjusting price cigarettes, adjusting price e-cigarettes, and both adjusting price cigarettes and e-cigarettes.
This study will have a set of hypothetical demand tasks for novel nicotine products. These tasks consist of different novel hypothetical products (combusted, oral, and vaporized) of differing nicotine content (high and low), and different flavors (preferred alcoholic flavor, no characterizing flavor) where likelihood to try is assessed at a variety of price points.
Demand Intensity for Hypothetical Nicotine Products
Demand intensity was assessed using hypothetical purchase tasks in which participants reported the number of products they would purchase at varying prices. In this case, demand intensity refers to the likelihood to try/consume a novel nicotine product when then cost of that product was free (i.e., likelihood to try at $0 ranging from 0-100).
Time frame: Baseline (study week 0) During the Hypothetical Purchase Task
Price Sensitivity for Hypothetical Nicotine Products
Demand sensitivity to novel hypothetical products was assessed for flavor, nicotine, and product type. Sensitivity was measured by finding the highest likelihood times cost per participant per condition, or the maximum likelihood expenditure (also referred to as Omax). Based on the task used, values can range from 0-5000.
Time frame: Baseline (study week 0) During the Hypothetical Purchase Task
Alternative Product Purchasing as a Function of Change in Price of Cigarettes and/or E-Cigarettes in the Experimental Tobacco Marketplace
Cigarette and e-cigarette users completed three different experimental tobacco marketplaces. They each completed a marketplace where e-cigarettes adjusted in price, another where cigarettes adjusted in price, and a third where both cigarettes and e-cigarettes adjusted in price. Then substitution for different product categories was assessed by the difference in amount spent in USD at the lowest price of the adjusting product to the highest price of the adjusting product. Positive values indicate an increase in consumption as a function of increasing cost of the adjusting price product (i.e., substitution).
Time frame: Baseline (study week 0) During the Hypothetical Purchase Task
| Milestone | Low Alcohol Use + No Cigarette/E-Cigarette Use | High Alcohol Use + No Cigarette/E-Cigarette Use | Low Alcohol Use + Cigarette/E-Cigarette Use | High Alcohol Use + Cigarette/E-Cigarette Use |
|---|---|---|---|---|
| Started | 200 | 161 | 157 | 219 |
| Completed | 200 | 161 | 157 | 219 |
| Not completed | 0 | 0 | 0 | 0 |
Demand intensity was assessed using hypothetical purchase tasks in which participants reported the number of products they would purchase at varying prices. In this case, demand intensity refers to the likelihood to try/consume a novel nicotine product when then cost of that product was free (i.e., likelihood to try at $0 ranging from 0-100).
| Number of Products Purchased | Low Alcohol Use + No Cigarette/E-Cigarette Use | High Alcohol Use + No Cigarette/E-Cigarette Use | Low Alcohol Use + Cigarette/E-Cigarette Use | High Alcohol Use + Cigarette/E-Cigarette Use |
|---|---|---|---|---|
| Oral Product Unflavored Low Nicotine Mean Intensity | 16.66 ± 31.93 | 19.24 ± 31.87 | 50.42 ± 44.86 | 61.9 ± 44.01 |
| Oral Product Unflavored High Nicotine Mean Intensity | 13.43 ± 28.24 | 17.01 ± 30.45 | 55.05 ± 45.07 | 65.51 ± 41.28 |
| Oral Product Flavored Low Nicotine Mean Intensity | 21.46 ± 34.68 | 23.79 ± 35.63 | 52.3 ± 45.79 | 60.8 ± 43.68 |
| Oral Product Flavored High Nicotine Mean Intensity | 17.96 ± 32.6 | 22.9 ± 35.16 | 53.91 ± 45.15 | 65.58 ± 41.52 |
| Vaporized Product Unflavored Low Nicotine Mean Intensity | 18.6 ± 33.03 | 15.97 ± 30.57 | 66.21 ± 41 | 74.08 ± 37.73 |
| Vaporized Product Unflavored High Nicotine Mean Intensity | 14.73 ± 29.37 | 15.24 ± 29.52 | 67.68 ± 41.44 | 79.11 ± 33.73 |
| Vaporized Product Flavored Low Nicotine Mean Intensity | 23.53 ± 35.53 | 24.43 ± 36.33 | 68.19 ± 41.8 | 73.09 ± 39.05 |
| Vaporized Product Flavored High Nicotine Mean Intensity | 19.42 ± 30.4 | 21.01 ± 27.43 | 67.14 ± 44.62 | 76.38 ± 39.45 |
| Combusted Product Unflavored Low Nicotine Mean Intensity | 16.38 ± 33.78 | 13.87 ± 33.43 | 51.68 ± 41.86 | 69.5 ± 36.6 |
| Combusted Product Unflavored High Nicotine Mean Intensity | 14.63 ± 29.16 | 15.95 ± 30.53 | 56.41 ± 44.53 | 75.58 ± 35.06 |
| Combusted Product Flavored Low Nicotine Mean Intensity | 22.2 ± 35.2 | 20.67 ± 34.72 | 55.36 ± 44.87 | 65.65 ± 40.98 |
| Combusted Product Flavored High Nicotine Mean Intensity | 18.84 ± 33.47 | 20.31 ± 33.8 | 54.96 ± 44.24 | 71.79 ± 38.62 |
Demand sensitivity to novel hypothetical products was assessed for flavor, nicotine, and product type. Sensitivity was measured by finding the highest likelihood times cost per participant per condition, or the maximum likelihood expenditure (also referred to as Omax). Based on the task used, values can range from 0-5000.
| Number of Products Bought per U.S.Dollar | Low Alcohol Use + No Cigarette/E-Cigarette Use | High Alcohol Use + No Cigarette/E-Cigarette Use | Low Alcohol Use + Cigarette/E-Cigarette Use | High Alcohol Use + Cigarette/E-Cigarette Use |
|---|---|---|---|---|
| Oral Product Unflavored Low Nicotine Mean Intensity | 92.48 ± 397.07 | 122.24 ± 550.11 | 160.79 ± 306.81 | 350.5 ± 826.99 |
| Oral Product Unflavored High Nicotine Mean Intensity | 84.05 ± 347.72 | 121.42 ± 579.77 | 222.22 ± 505.57 | 390.29 ± 787.1 |
| Oral Product Flavored Low Nicotine Mean Intensity | 134.8 ± 432.8 | 134.08 ± 586.39 | 270.56 ± 647.17 | 408.97 ± 890.18 |
| Oral Product Flavored High Nicotine Mean Intensity | 126.65 ± 474.2 | 127.13 ± 563.35 | 255.25 ± 459.25 | 451.51 ± 877.31 |
| Vaporized Product Unflavored Low Nicotine Mean Intensity | 90.22 ± 357.9 | 139.17 ± 658.91 | 295.73 ± 516.33 | 465.92 ± 799.81 |
| Vaporized Product Unflavored High Nicotine Mean Intensity | 98.92 ± 491.33 | 136.93 ± 635.64 | 364.84 ± 668.99 | 596.02 ± 903.68 |
| Vaporized Product Flavored Low Nicotine Mean Intensity | 168.25 ± 569.19 | 161.78 ± 708.2 | 432.2 ± 694.47 | 526.71 ± 929.17 |
| Vaporized Product Flavored High Nicotine Mean Intensity | 113.22 ± 421.38 | 153.86 ± 645.09 | 472.01 ± 753.63 | 677.82 ± 999.08 |
| Combusted Product Unflavored Low Nicotine Mean Intensity | 112.32 ± 447.39 | 104.5 ± 490.11 | 186.58 ± 403.25 | 365.93 ± 715.6 |
| Combusted Product Unflavored High Nicotine Mean Intensity | 85.98 ± 349.21 | 108.11 ± 474.93 | 242.78 ± 450.25 | 458.02 ± 800.12 |
| Combusted Product Flavored Low Nicotine Mean Intensity | 163.67 ± 593.53 | 163.85 ± 629.11 | 267.18 ± 480.95 | 444.24 ± 857.65 |
| Combusted Product Flavored High Nicotine Mean Intensity | 143.3 ± 488.66 | 138 ± 524.51 | 321.26 ± 554.91 | 527.08 ± 899.86 |
Cigarette and e-cigarette users completed three different experimental tobacco marketplaces. They each completed a marketplace where e-cigarettes adjusted in price, another where cigarettes adjusted in price, and a third where both cigarettes and e-cigarettes adjusted in price. Then substitution for different product categories was assessed by the difference in amount spent in USD at the lowest price of the adjusting product to the highest price of the adjusting product. Positive values indicate an increase in consumption as a function of increasing cost of the adjusting price product (i.e., substitution).
| Number of Products Bought per U.S.Dollar | Low Alcohol Use + No Cigarette/E-Cigarette Use | High Alcohol Use + No Cigarette/E-Cigarette Use | Low Alcohol Use + Cigarette/E-Cigarette Use | High Alcohol Use + Cigarette/E-Cigarette Use |
|---|---|---|---|---|
| E-Cigarette Marketplace Combusted Product Substitution | — | — | 0.69 ± 4.09 | 0.48 ± 2.87 |
| E-Cigarette Marketplace Non-Combusted Product Substitution | — | — | 0.26 ± 0.88 | 0.19 ± 0.79 |
| E-Cigarette Marketplace Quit Product Substitution | — | — | 0.08 ± 0.5 | 0.02 ± 0.47 |
| E-Cigarette Marketplace Cigarettes Product Substitution | — | — | 0.03 ± 1.46 | 0.13 ± 1.49 |
| Cigarette Marketplace Combusted Product Substitution | — | — | 1.87 ± 6.9 | 1.39 ± 4.65 |
| Cigarette Marketplace Non-Combusted Product Substitution | — | — | 0.14 ± 1.04 | 0.21 ± 1.27 |
| Cigarette Marketplace Quit Product Substitution | — | — | 0.06 ± 0.41 | 0 ± 0.21 |
| Cigarette Marketplace E-Cigarettes Product Substitution | — | — | 0.01 ± 1.34 | 0.35 ± 1.73 |
| Combined Marketplace Combusted Product Substitution | — | — | 2.01 ± 4.96 | 2.29 ± 5.72 |
| Combined Marketplace Non-Combusted Product Substitution | — | — | 0.45 ± 1.15 | 0.31 ± 1.39 |
| Combined Marketplace Quit Product Substitution | — | — | 0.14 ± 0.54 | 0.13 ± 0.52 |
Collected over 60 Minutes. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Low Alcohol Use + No Cigarette/E-Cigarette Use | 0/200 (0%) | 0/200 (0%) | 0/200 (0%) |
| High Alcohol Use + No Cigarette/E-Cigarette Use | 0/161 (0%) | 0/161 (0%) | 0/161 (0%) |
| Low Alcohol Use + Cigarette/E-Cigarette Use | 0/157 (0%) | 0/157 (0%) | 0/157 (0%) |
| High Alcohol Use + Cigarette/E-Cigarette Use | 0/219 (0%) | 0/219 (0%) | 0/219 (0%) |
The number of participants reported in each arm described here is prior to any data quality checks based on participants responding to embedded attention checks in the surveys or if participants responded in an inconsistent manner for the types of tobacco products they reported using.
| Age, Continuous(years) | Low Alcohol Use + No Cigarette/E-Cigarette Use | High Alcohol Use + No Cigarette/E-Cigarette Use | Low Alcohol Use + Cigarette/E-Cigarette Use | High Alcohol Use + Cigarette/E-Cigarette Use | Total |
|---|---|---|---|---|---|
| Mean | 46.46 ± 13.04 | 44 ± 12.05 | 43.41 ± 12.13 | 39.95 ± 10.88 | 43.4 ± 12.27 |
| Sex: Female, Male(Participants) | Low Alcohol Use + No Cigarette/E-Cigarette Use | High Alcohol Use + No Cigarette/E-Cigarette Use | Low Alcohol Use + Cigarette/E-Cigarette Use | High Alcohol Use + Cigarette/E-Cigarette Use | Total |
|---|---|---|---|---|---|
| Female | 96 | 56 | 85 | 80 | 317 |
| Male | 96 | 94 | 66 | 129 | 385 |
| Race (NIH/OMB)(Participants) | Low Alcohol Use + No Cigarette/E-Cigarette Use | High Alcohol Use + No Cigarette/E-Cigarette Use | Low Alcohol Use + Cigarette/E-Cigarette Use | High Alcohol Use + Cigarette/E-Cigarette Use | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 2 | 1 | 3 |
| Asian | 10 | 5 | 3 | 7 | 25 |
| Native Hawaiian or Other Pacific Islander | 3 | 0 | 0 | 0 | 3 |
| Black or African American | 15 | 15 | 20 | 24 | 74 |
| White | 152 | 121 | 113 | 158 | 544 |
| More than one race | 12 | 9 | 13 | 19 | 53 |
| Unknown or Not Reported | 0 | 0 | 0 | 1 | 1 |
| Ethnicity (NIH/OMB)(Participants) | Low Alcohol Use + No Cigarette/E-Cigarette Use | High Alcohol Use + No Cigarette/E-Cigarette Use | Low Alcohol Use + Cigarette/E-Cigarette Use | High Alcohol Use + Cigarette/E-Cigarette Use | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 9 | 6 | 1 | 6 | 22 |
| Not Hispanic or Latino | 183 | 144 | 150 | 204 | 681 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Low Alcohol Use + No Cigarette/E-Cigarette Use | High Alcohol Use + No Cigarette/E-Cigarette Use | Low Alcohol Use + Cigarette/E-Cigarette Use | High Alcohol Use + Cigarette/E-Cigarette Use | Total |
|---|---|---|---|---|---|
| United States | 200 | 161 | 157 | 219 | 737 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Deidentified data from this study will be made as available as possible after acceptance for publication. All shared data will comply with HIPAA guidelines on personally identifiable information. Code used for analyses will also accompany deidentified data.
Supporting information: Analytic code
Ran from Aug 2025 to primary completion in Aug 2025, 0 months.
Results were first posted in Oct 2026, 1 year 1 month after primary completion.
Of 184 non-industry interventional studies with no phase under Vaping, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 35. This study's 0 months is below that.
Counting every sponsor, half of 208 studies reached it within 18 months; a quarter within 6 and three quarters within 32.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Mark J Rzeszutek, PhD